



JAPAN TOBACCO INC.
2-1, Toranomom 2-chome, Minato-ku
Tokyo 105-8422 JAPAN
Phone:03-3582-3111

FOR IMMEDIATE RELEASE

Tokyo, January 22, 2018

Notice Concerning Amendments to Earnings Forecasts of JT's Subsidiary

Japan Tobacco Inc. (JT) today announced that Torii Pharmaceutical Co., Ltd., a consolidated subsidiary of JT, has amended the full-year earnings forecasts for the December 2017 term (January 1, 2017 through December 31, 2017) as shown in the attached sheet.

The effects of this amendment on JT's consolidated financial results will be immaterial.

(Attachment)

Reference: "Torii Amends Full-Year Earnings Forecasts for Fiscal Year Ended December 31, 2017"
(Materials released by Torii Pharmaceutical Co., Ltd. as of January 22, 2018)

###

Japan Tobacco Inc. is a leading international tobacco company. Its products are sold in over 120 countries and its globally recognized brands include Winston, Camel, Mevius, LD and Natural American Spirit. With diversified operations, JT is also actively present in pharmaceuticals and processed foods. The Company's revenue was ¥2.143 trillion (US\$19,703 million^()) in the fiscal year ended December 31, 2016.*

^(*)Translated at the rate of ¥108.78 per \$1

Contact: Masahito Shirasu, General Manager
Media and Investor Relations Division
Japan Tobacco Inc. Tokyo: +81-3-5572-4292
E-mail: jt.media.relations@jt.com

Torii Amends Full-Year Earnings Forecasts for Fiscal Year Ended December 31, 2017

In consideration of the recent trend in earnings and other factors, Torii Pharmaceutical Co., Ltd. ("Torii") has amended its full-year earnings forecasts for the fiscal year ended December 31, 2017, which were announced on October 26, 2017, as described below.

1. Amendments to Full-Year Earnings Forecasts for Fiscal Year Ended December 31, 2017
(January 1, 2017, through December 31, 2017)

	Net sales (Millions of yen)	Operating income (Millions of yen)	Ordinary income (Millions of yen)	Net income (Millions of yen)	Net income per share (Yen)
Previous forecasts (A)	63,100	5,000	5,100	3,800	135.48
New forecasts (B)	64,130	6,280	6,400	4,710	167.92
Amount of change (B-A)	1,030	1,280	1,300	910	
Rate of change (%)	1.6	25.6	25.5	23.9	
(Reference) Actual cumulative amount for January to December 2016 (Note)	60,206	3,819	3,999	2,839	100.41

2. Reasons for Amendments

Net sales are now expected to be slightly higher than the previously announced forecast figures due to the mainstay product "REMITCH (an oral pruritus treatment in dialysis patients)" sales are strong. Operating income and ordinary income are expected to exceed the previously announced forecast figures due to the positive effects of cost saving initiatives and some deferred expenses to next year in both R&D and sales. As a result, net income is also expected to be higher than the previously announced forecast figures.

*The above-mentioned earnings forecasts are based on information available to Torii as of the date of this announcement. Actual business results may differ from the forecast figures herein.